The mechanisms by which these activators exert their beneficiary effects are currently under extensive research, highlighting the importance of developing therapies to increase either SIRT1 expression or activity in patients with DKD to prevent disease progression. The gene discussed is SIRT1; the disease is diabetic kidney disease.